Sandra Oršulić

21.4k total citations · 2 hit papers
95 papers, 6.8k citations indexed

About

Sandra Oršulić is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Sandra Oršulić has authored 95 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 33 papers in Oncology and 23 papers in Reproductive Medicine. Recurrent topics in Sandra Oršulić's work include Ovarian cancer diagnosis and treatment (22 papers), Cancer Cells and Metastasis (13 papers) and Wnt/β-catenin signaling in development and cancer (9 papers). Sandra Oršulić is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Cancer Cells and Metastasis (13 papers) and Wnt/β-catenin signaling in development and cancer (9 papers). Sandra Oršulić collaborates with scholars based in United States, China and Japan. Sandra Oršulić's co-authors include Mark Peifer, David H. Raulet, Eric J. Brown, Stephan Gasser, Dong‐Joo Cheon, Deyin Xing, Rolf Kemler, Beth Y. Karlan, Sebastian J. Arnold and Hermann Aberle and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Sandra Oršulić

92 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

2005 1.0k citations Sandra Oršulić et al. profile →
Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas

2024 52 citations Sandra Oršulić et al. profile →

Peers

Countries citing papers authored by Sandra Oršulić

Since Specialization

Citations

This map shows the geographic impact of Sandra Oršulić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Oršulić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Oršulić more than expected).

Fields of papers citing papers by Sandra Oršulić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Oršulić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Oršulić. The network helps show where Sandra Oršulić may publish in the future.

Co-authorship network of co-authors of Sandra Oršulić

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Oršulić. A scholar is included among the top collaborators of Sandra Oršulić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Oršulić. Sandra Oršulić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer 2024 ·npj Precision Oncology ·Ye Hu, (unknown), Marcela Haro, Enes Taylan, Barbie Taylor‐Harding, Ann E. Walts, Beth Y. Karlan, Sandra Oršulić	15
2	Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma 2024 ·Science Advances ·Alexander M. Xu, Marcela Haro, Ann E. Walts, Ye Hu, Joshi John, Beth Y. Karlan, Akil Merchant, Sandra Oršulić	14
3	Metabolic dependencies and targets in ovarian cancer 2023 ·Pharmacology & Therapeutics ·Yaqi Zhang, Yinu Wang, Guangyuan Zhao, Sandra Oršulić, Daniela Matei	32
4	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers 2022 ·Cells ·Arkadiusz Gertych, Ann E. Walts, (unknown), (unknown), Joshi John, Jenny Lester, Beth Y. Karlan, Sandra Oršulić	12
5	Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis 2021 ·Cell Reports ·Nur Yucer, (unknown), Michael J. Workman, Alex Laperle, (unknown), Kathleen Kurowski, (unknown), (unknown), Ying Qu, Jasmine Plummer, Simon A. Gayther, Sandra Oršulić, Beth Y. Karlan, Clive N. Svendsen	31
6	Immunological configuration of ovarian carcinoma: features and impact on disease outcome 2021 ·Journal for ImmunoTherapy of Cancer ·Jitka Fučíková, An Coosemans, Sandra Oršulić, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Špíšek	33
7	Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model 2015 ·Cancer Immunology Research ·Lei Wang, Zohreh Amoozgar, Jing Huang, Mohammad H. Saleh, Deyin Xing, Sandra Oršulić, Michael S. Goldberg	132
8	A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer 2013 ·Clinical Cancer Research ·Dong‐Joo Cheon, Yunguang Tong, Myung‐Shin Sim, Judy Dering, Dror Berel, Xiaojiang Cui, Jenny Lester, Jessica A. Beach, Mourad Tighiouart, Ann E. Walts, Beth Y. Karlan, Sandra Oršulić	265
9	CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer 2011 ·Cancer Research ·Elda Righi, Satoshi Kashiwagi, J. P. Yuan, Michael Santosuosso, Pierre Leblanc, Rachel Ingraham, Benjamin Forbes, (unknown), Brian Collette, Deyin Xing, (unknown), Maria Cristina Mingari, Fabrizio Vianello, Michael J. Birrer, Sandra Oršulić, Glenn Dranoff, Mark C. Poznansky	191
10	Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment 2011 ·British Journal of Cancer ·Barbie Taylor‐Harding, Hasmik Agadjanian, Hoorig Nassanian, (unknown), Xiaoqing Guo, Catherine Miller, Beth Y. Karlan, Sandra Oršulić, Christine Walsh	31
11	BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma 2010 ·Cancer Research ·Nageatte Ibrahim, Lei He, Chee-Onn Leong, Deyin Xing, Beth Y. Karlan, Elizabeth M. Swisher, Bo R. Rueda, Sandra Oršulić, Leif W. Ellisen	41
12	Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells 2010 ·Proceedings of the National Academy of Sciences ·Michael S. Goldberg, Deyin Xing, Yin Ren, Sandra Oršulić, Sangeeta N. Bhatia, Phillip A. Sharp	83
13	Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene 2010 ·Cancer Research ·(unknown), Runsheng Wang, Jiangyong Miao, Esther Oliva, Xiaoyun Shen, Thomas M. Wheeler, Susan G. Hilsenbeck, Sandra Oršulić, Scott R. Goode	219
14	A Role for BRCA1 in Uterine Leiomyosarcoma 2009 ·Cancer Research ·Deyin Xing, (unknown), Mai Nitta, Lei He, Xuan Xu, Yevgeniya Ioffe, Paul‐Joseph Aspuria, (unknown), Matthew L. Anderson, Esther Oliva, Beth Y. Karlan, Gayatry Mohapatra, Sandra Oršulić	47
15	Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-δ Signaling in Epithelial Ovarian Cancer 2007 ·Cancer Research ·Takiko Daikoku, Susanne Tranguch, Anindita Chakrabarty, Dingzhi Wang, Dineo Khabele, Sandra Oršulić, Jason D. Morrow, Raymond N. DuBois, Sudhansu K. Dey	39
16	A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma 2006 ·Cancer Research ·Deyin Xing, Sandra Oršulić	98
17	Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer 2005 ·Cancer Research ·Takiko Daikoku, Dingzhi Wang, Susanne Tranguch, Jason D. Morrow, Sandra Oršulić, Raymond N. DuBois, Sudhansu K. Dey	114
18	Modeling Resistance to Pathway-Targeted Therapy in Ovarian Cancer 2005 ·Cell Cycle ·Deyin Xing, Sandra Oršulić	17
19	Expression of Eph receptors and ephrins is differentially regulated by E-cadherin 2000 ·Journal of Cell Science ·Sandra Oršulić, Rolf Kemler	108
20	Cell–cell signalling: Wingless lands at last 1996 ·Current Biology ·Sandra Oršulić, Mark Peifer	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact